ALX Oncology Holdings Inc. (ALXO)
NASDAQ$0.7836
Market Cap
$41.83M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
270 of 924
Rank in Industry
156 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ALXO Insider Trading Activity
ALXO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $148,742 | 2 | 10 |
Sells | $1,907,216 | 19 | 90 |
Related Transactions
| GARCIA PETER S | CHIEF FINANCIAL OFFICER | 1 | $102,338 | 0 | $0 | $102,338 |
| Hemrajani Rekha | director | 1 | $46,404 | 0 | $0 | $46,404 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 0 | $0 | 1 | $2,483 | $-2,483 |
| Pinto Shelly | SVP, FINANCE AND CAO | 0 | $0 | 6 | $26,353 | $-26,353 |
| Randolph Sophia | CHIEF MEDICAL OFFICER | 0 | $0 | 3 | $213,905 | $-213,905 |
| Pons Jaume | PRESIDENT & CSO | 0 | $0 | 9 | $1.66M | $-1.66M |
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction …
Insider Activity of ALX Oncology Holdings Inc.
Over the last 12 months, insiders at ALX Oncology Holdings Inc. have bought $148,742 and sold $1.91M worth of ALX Oncology Holdings Inc. stock.
On average, over the past 5 years, insiders at ALX Oncology Holdings Inc. have bought $52.18M and sold $9.08M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GARCIA PETER S (CHIEF FINANCIAL OFFICER) — $102,338. Hemrajani Rekha (director) — $46,404.
The last purchase of 30,000 shares for transaction amount of $46,404 was made by Hemrajani Rekha (director) on 2024‑12‑02.
List of Insider Buy and Sell Transactions, ALX Oncology Holdings Inc.
| 2025-02-19 | Sale | Pons Jaume | PRESIDENT & CSO | 1,326 0.0025% | $1.15 | $1,525 | -10.68% | |
| 2025-02-19 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 2,159 0.004% | $1.15 | $2,483 | -10.68% | |
| 2025-02-19 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 550 0.001% | $1.15 | $633 | -10.68% | |
| 2025-01-06 | Sale | Pinto Shelly | Interim CFO | 2,221 0.0043% | $1.80 | $3,998 | -34.64% | |
| 2024-12-30 | Sale | Pons Jaume | PRESIDENT & CSO | 10,796 0.02% | $1.58 | $17,060 | -27.71% | |
| 2024-12-30 | Sale | Pinto Shelly | Interim CFO | 1,426 0.0026% | $1.58 | $2,253 | -27.71% | |
| 2024-12-02 | Hemrajani Rekha | director | 30,000 0.0532% | $1.55 | $46,404 | -11.45% | ||
| 2024-08-14 | Sale | Pons Jaume | PRESIDENT & CSO | 1,937 0.0038% | $2.58 | $4,997 | -39.92% | |
| 2024-08-14 | Sale | Randolph Sophia | CHIEF MEDICAL OFFICER | 1,365 0.0027% | $2.58 | $3,522 | -39.92% | |
| 2024-08-14 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 564 0.0011% | $2.58 | $1,455 | -39.92% | |
| 2024-07-11 | Sale | Pons Jaume | PRESIDENT & CSO | 20,000 0.0516% | $7.90 | $158,076 | -78.96% | |
| 2024-07-05 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 1,823 0.0033% | $5.50 | $10,025 | -70.09% | |
| 2024-07-01 | Sale | Pons Jaume | PRESIDENT & CSO | 10,758 0.0204% | $5.82 | $62,599 | -72.79% | |
| 2024-07-01 | Sale | Randolph Sophia | CHIEF MEDICAL OFFICER | 3,273 0.0062% | $5.82 | $19,045 | -72.79% | |
| 2024-07-01 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 1,373 0.0026% | $5.82 | $7,989 | -72.79% | |
| 2024-06-13 | GARCIA PETER S | CHIEF FINANCIAL OFFICER | 12,000 0.0229% | $8.53 | $102,338 | -80.27% | ||
| 2024-06-04 | Sale | Pons Jaume | PRESIDENT & CSO | 20,000 0.0387% | $8.43 | $168,652 | -79.81% | |
| 2024-05-13 | Sale | Randolph Sophia | CHIEF MEDICAL OFFICER | 12,000 0.0243% | $15.94 | $191,339 | -88.44% | |
| 2024-05-06 | Sale | Pons Jaume | PRESIDENT & CSO | 20,000 0.0399% | $15.92 | $318,334 | -88.53% | |
| 2024-04-16 | Sale | Pons Jaume | PRESIDENT & CSO | 50,000 0.0977% | $14.20 | $710,195 | -87.16% |
Total: 76
*Gray background shows transactions not older than one year
Insider Historical Profitability
64.8%
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 170270 0.319% | $133,423.57 | 2 | 5 | +4.84% |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER | 122348 0.2292% | $95,871.89 | 2 | 8 | +90.48% |
| Hemrajani Rekha | director | 33000 0.0618% | $25,858.80 | 2 | 0 | +90.48% |
| Adelman Robert J | 5268325 9.8687% | $4.13M | 1 | 0 | +90.48% | |
| Graham G. Walmsley | director | 995000 1.8639% | $779,682.00 | 2 | 0 | +34.88% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$4,273,853 | 101 | -36.67% | $43.68M | |
$1,695,621 | 55 | 17.90% | $44.29M | |
$140,938,207 | 36 | 14.75% | $41.76M | |
$23,895,365 | 34 | -37.28% | $37.97M | |
$241,165 | 22 | -16.72% | $40.55M |
ALXO Institutional Investors: Active Positions
| Increased Positions | 52 | +47.71% | 8M | +18.02% |
| Decreased Positions | 46 | -42.2% | 13M | -27.68% |
| New Positions | 21 | New | 3M | New |
| Sold Out Positions | 27 | Sold Out | 5M | Sold Out |
| Total Postitions | 115 | +5.5% | 41M | -9.66% |
ALXO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Venbio Partners Llc | $8,051.00 | 18.3% | 9.7M | 0 | 0% | 2024-12-31 |
| Redmile Group, Llc | $3,062.00 | 6.96% | 3.69M | -146,965 | -3.83% | 2024-12-31 |
| Tang Capital Management Llc | $2,736.00 | 6.22% | 3.3M | -907,852 | -21.59% | 2024-12-31 |
| Morgan Stanley | $2,074.00 | 4.72% | 2.5M | +2M | +679.09% | 2024-12-31 |
| Blackrock, Inc. | $1,979.00 | 4.5% | 2.38M | -217,529 | -8.36% | 2024-12-31 |
| Millennium Management Llc | $1,767.00 | 4.02% | 2.13M | +126,736 | +6.33% | 2024-12-31 |
| Vanguard Group Inc | $1,566.00 | 3.56% | 1.89M | +2,429 | +0.13% | 2024-12-31 |
| Fmr Llc | $1,537.00 | 3.49% | 1.85M | -4M | -68.43% | 2024-12-31 |
| Mpm Bioimpact Llc | $1,155.00 | 2.63% | 1.39M | -1M | -42.26% | 2024-12-31 |
| Almitas Capital Llc | $1,015.00 | 2.31% | 1.22M | +1M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.